Toward the molecular dissection of primary biliary cirrhosis

Hepatology

Volumn 50, Issue 5, 2009, Pages 1347-1350

  Hirschfield, Gideon M ^a   Siminovitch, Katherine A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HLA ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR; INTERLEUKIN 12 RECEPTOR BETA2; INTERLEUKIN 12P35; INTERLEUKIN 12P40; STAT4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

AUTOIMMUNE DISEASE; CHOLANGITIS; DISEASE COURSE; DISEASE MODEL; EDITORIAL; ENVIRONMENTAL FACTOR; GENE MAPPING; GENETIC ANALYSIS; GENETIC ASSOCIATION; HEREDITY; HISTOPATHOLOGY; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-12; LIVER CIRRHOSIS, BILIARY; MICE; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 72949118302     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.23252     Document Type: Editorial

References (20)

1. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. Primary biliary cirrhosis. HEPATOLOGY 2009;50:291-308.
2. Gershwin ME, Mackay IR. The causes of primary biliary cirrhosis: Convenient and inconvenient truths. HEPATOLOGY 2008;47:737-745.
3. Yoshida K, Yang GX, Zhang W, Tsuda M, Tsuneyama K, Moritoki Y, et al. Deletion of IL-12p40 suppresses autoimmune cholangitis in dnTGFβRII mice. HEPATOLOGY 2009;50:1494-1500.
4. Hirschfield GM, Liu X, Xu C, Lu Y, Xie G, Lu Y, et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med 2009;360:2544-2555.
5. Irie J, Wu Y, Wicker LS, Rainbow D, Nalesnik MA, Hirsch R, et al. NOD.c3c4 congenic mice develop autoimmune biliary disease that serologically and pathogenetically models human primary biliary cirrhosis. J Exp Med 2006;203:1209-1219.
6. Zhang W, Sharma R, Ju ST, He XS, Tao Y, Tsuneyama K, et al. Deficiency in regulatory T cells results in development of antimitochondrial antibodies and autoimmune cholangitis. HEPATOLOGY 2009;49:545-552.
7. Salas JT, Banales JM, Sarvide S, Recalde S, Ferrer A, Uriarte I, et al. Ae2a,b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis. Gastroenterology 2008;134: 1482-1493.
8. Wakabayashi K, Yoshida K, Leung PS, Moritoki Y, Yang GX, Tsuneyama K, et al. Induction of autoimmune cholangitis in non-obese diabetic (NOD).1101 mice following a chemical xenobiotic immunization. Clin Exp Immunol 2009;155:577-586.
9. Oertelt S, Lian ZX, Cheng CM, Chuang YH, Padgett KA, He XS, et al. Anti-mitochondrial antibodies and primary biliary cirrhosis in TGFbeta receptor II dominant-negative mice. J Immunol 2006;177:1655-1660.
10. Goriely S, Cavoy R, Goldman M. Interleukin-12 family members and type I interferons in Th17-mediated inflammatory disorders. Allergy 2009;64: 702-709.
11. Awasthi A, Kuchroo VK. Th17 cells: from precursors to players in inflammation and infection. Int Immunol 2009;21:489-498.
12. Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callis KP, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007;80:273-290.
13. Hunt KA, Zhernakova A, Turner G, Heap GA, Franke L, Bruinenberg M, et al. Newly identified genetic risk variants for celiac disease related to the immune response. Nat Genet 2008;40:395-402.
14. Goriely S, Neurath MF, Goldman M. How microorganisms tip the balance between interleukin-12 family members. Nat Rev Immunol 2008;8:81-86.
15. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371:1665-1674.
16. Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004;351:2069-2079.
17. Burakoff R, Barish CF, Riff D, Pruitt R, Chey WY, Farraye FA, et al. A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease. Inflamm Bowel Dis 2006;12:558-565.
18. Rong G, Zhou Y, Xiong Y, Zhou L, Geng H, Jiang T, et al. Imbalance between T helper type 17 and T regulatory cells in patients with primary biliary cirrhosis: the serum cytokine profile and peripheral cell population. Clin Exp Immunol 2009;156:217-225.
19. Harada K, Shimoda S, Sato Y, Isse K, Ikeda H, Nakanuma Y. Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis. Clin Exp Immunol 2009;157:261-270.
20. Lan RY, Salunga TL, Tsuneyama K, Lian ZX, Yang GX, Hsu W, et al. Hepatic IL-17 responses in human and murine primary biliary cirrhosis. J Autoimmun 2009;32:43-51.